First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

• Published in: Communications medicine Vol. 4; no. 1; p. 10
• Main Authors: Mahalingam, Devalingam, Harb, Wael, Patnaik, Amita, Bullock, Andrea, Watnick, Randolph S., Vincent, Melanie Y., Chen, Jian Jenny, Wang, Suming, Pestana, Harold, Chao, Judy, Mahoney, James, Cieslewicz, Michael, Watnick, Jing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.01.2024; Springer Nature B.V; Nature Portfolio
• Subjects: 631/67/1059/153; 692/4028/67/1059/153; 692/4028/67/1059/2325; Apoptosis; Biopsy; Bone marrow; Cancer therapies; Clinical outcomes; Disease control; Drug dosages; Mass spectrometry; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Ovarian cancer; Patients; Pharmacokinetics; Prostate; Scientific imaging; Toxicity; Tumors

Background VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding to CD36 and CD47 to induce tumor and endothelial cell apoptosis as well as imm...